We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Open Label Study of Duloxetine for the Treatment of Phantom Limb Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00425230
Recruitment Status : Terminated (No patients were enrolled in this study. The study onset was delayed due to problems with drug acquisition.)
First Posted : January 22, 2007
Last Update Posted : December 22, 2010
Information provided by:
Baylor College of Medicine

January 19, 2007
January 22, 2007
December 22, 2010
January 2007
Not Provided
McGill Short Form Pain Questionairre
Same as current
Complete list of historical versions of study NCT00425230 on ClinicalTrials.gov Archive Site
  • Fiser Side effect scale
  • visual analog pain scale
  • Present Pain intensity
  • Tylenol # 3 consumption
Same as current
Not Provided
Not Provided
Open Label Study of Duloxetine for the Treatment of Phantom Limb Pain
Pilot Study of Use of Duloxetine for the Treatment of Phantom Limb Pain
This is a study to assess the possible benefit of duloxetine in the treatment of chronic phantom limb pain.
Not Provided
Not Provided
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Chronic Phantom Limb Pain
Drug: Duloxetine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
June 2007
Not Provided

Inclusion Criteria:

  1. Chronic PLP > 6 months
  2. Short-Form McGill Pain Questionnaire Sensory Pain Rating Index raw score ≥ 16
  3. Age ≥ 18 years old
  4. Inpatient or Outpatient
  5. Able to come to all appointments, in the opinion of the investigator
  6. Able to give informed consent, in opinion of investigator

Exclusion Criteria:

  1. Current Major Depressive disorder, Anxiety Disorder, or Psychotic disorder assessed by the Mini International Neuropsychiatric Interview (MINI)
  2. Substance abuse or dependence within the last six months, as assessed by the MINI
  3. Known Diabetes Mellitus to exclude diabetic peripheral neuropathy
  4. History of coronary artery disease, hepatic disease, renal disease
  5. Other pain syndromes
  6. Any unstable medical conditions in the opinion of the investigator
  7. Other psychotropic medications excluding hypnotics
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
Baylor College of Medicine
Not Provided
Principal Investigator: Asif Chaudhry, MD Baylor College of Medicine
Baylor College of Medicine
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP